Compare Recursion Pharmaceuticals Inc (RXRX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs VanEck Vietnam ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while VanEck Vietnam ETF trades at $17.85. The key difference: VanEck Vietnam ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VNM | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $19.80 |
52-Week Low | $2.84 | $16.34 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
VNM trades at $17.91, down 1.38% for the day, with a technical outlook leaning bearish based on moving averages. The ETF's performance is challenged by its heavy concentration in Vietnamese real estate and financials, exposing it to sector-specific volatility. Recent news highlights underperformance relative to other emerging markets, though potential exists from FTSE Russell's upcoming EM reclassification in September 2026, which may attract foreign institutional flows.
The outlook remains cautious due to near-term headwinds from sector concentration and macroeconomic factors in Vietnam. Investment opportunity hinges on the country's long-term growth trajectory and potential inflows from index changes, but risks from interest rate sensitivity and concentrated holdings warrant careful consideration for investors seeking emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
